The generic version of Dydrogesterone Tablets developed by Aurisco Pharmaceutical Co Ltd. [Photo/taizhou.com.cn]

Aurisco Pharmaceutical Co Ltd, based in Taizhou's Tiantai county, has achieved a significant milestone with the development of its generic version of Dydrogesterone Tablets.

The National Medical Products Administration (NMPA) has issued the company a Drug Registration Certificate for this groundbreaking product, the first oral solid preparation created in Tiantai.

Dydrogesterone Tablets have been widely used in foreign markets and have benefited over 40 million patients. However, due to the intricate synthetic process and high technical requirements, developing generic versions of this hormone-like medication has been challenging. Thus, Aurisco's success marks a monumental breakthrough, as there have been scarce generic alternatives available globally in the nearly 60 years since its introduction.

Primarily utilized to alleviate symptoms of endometriosis, a condition caused by the growth of womb lining outside the uterus, Dydrogesterone also aids in treating infertility caused by low progesterone levels.

Established in 1998, Aurisco has consistently demonstrated its commitment to pharmaceutical excellence. The company boasts a diverse range of products spanning key therapeutic areas, including respiratory, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health. Aurisco's products have obtained approvals for export to coveted markets such as the European Union and the United States.